Please assess the completion status of the following clinical trial:

Trial Title: Test-Retest Reproducibility of 18F-DCFPyL PET/CT in the Evaluation of Patients With Metastatic Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to provide written informed consent~* History of histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell histology~* Patients with metastatic castration-sensitive (CSPC) or castration-resistant prostate cancer (CRPC) with evidence of metastatic disease on conventional imaging with CT or bone scan.~* Prior docetaxel-based chemotherapy is permitted~* Documented metastatic prostate cancer progression as assessed by the treating oncologist with either one or both of the following and has not initiated a new therapy after determination of progression: Rising PSA over a minimum 1-week interval and/or radiographic progression in soft tissue and bone metastases (combination of bony and soft tissue metastases)~* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2~Exclusion Criteria:~* Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection~* Administered a radioisotope ≤5 physical half-lives prior to the date of study PET/CT~* Administered IV X-ray contrast medium ≤24 hours prior to the date of study PET/CT~* Administered oral contrast medium ≤120 hours prior to the date of study PET/CT~* Condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with patient's participation in the study

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 18F-DCFPyL Injection (Type: EXPERIMENTAL): 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL

Based on this trial design, predict the completion outcome and termination type (if applicable).